Literature DB >> 11036495

Epithelioid granuloma in the iris of a lepromatous leprosy patient; an unusual finding.

E Daniel1, G J Ebenezer, T J ffytche, A Sigamani, C K Job.   

Abstract

This case report depicts a case of histopathologically confirmed polar lepromatous (LL) leprosy with a bacterial index of 4+. He experienced recurrent episodes of erythema nodosum leprosum (ENL) in the first 5 years after diagnosis. Skin smears became negative after 6 years of dapsone monotherapy and have remained negative since that time. At 23 years after diagnosis, the patient had developed cataracts and underwent intracapsular cataract extractions with broad-based iridectomies. In one of the iris specimens, histopathologic examination revealed a focal granuloma composed of epithelioid cells. Subsequently a lepromin skin test showed a positive Mitsuda reaction with a borderline tuberculoid histopathology. This clearly illustrates the immunological upgrading of a polar lepromatous patient, perceived first in the iris tissue.

Entities:  

Mesh:

Year:  2000        PMID: 11036495

Source DB:  PubMed          Journal:  Int J Lepr Other Mycobact Dis        ISSN: 0148-916X


  3 in total

1.  Incidence of ocular morbidity among multibacillary leprosy patients during a 2 year course of multidrug therapy.

Authors:  E Daniel; T J Ffytche; P S S Sundar Rao; J H Kempen; M Diener-West; P Courtright
Journal:  Br J Ophthalmol       Date:  2006-05       Impact factor: 4.638

2.  Incidence of ocular complications in patients with multibacillary leprosy after completion of a 2 year course of multidrug therapy.

Authors:  E Daniel; T J Ffytche; J H Kempen; P S S Sundar Rao; M Diener-West; P Courtright
Journal:  Br J Ophthalmol       Date:  2006-05-17       Impact factor: 4.638

3.  Expression of protein gene product 9.5 in lepromatous eyes showing ciliary body nerve damage and a "dying back" phenomenon in the posterior ciliary nerves.

Authors:  G J Ebenezer; E Daniel
Journal:  Br J Ophthalmol       Date:  2004-02       Impact factor: 4.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.